Tempest Therapeutics, Inc.
TPST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001544227
No open-market purchases or sales by Tempest Therapeutics, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.44M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Tempest Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 24 | 22 | −2 |
| Shares | 1.84M | 2.20M | +360.6K (+19.6%) |
| Value | $20.5M | $31.8M | +$11.2M (+54.8%) |
New holders (3)
Institutions that held Tempest Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 29,072 | $421.0K | 0.00% |
| Geode Capital Management, LLC | 23,301 | $337.0K | 0.00% |
| Franklin Resources Inc | 15,240 | $221.0K | 0.00% |
Sold out (5)
Institutions that held Tempest Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Boothbay Fund Management, LLC | 10,477 | $117.0K |
| Acadian Asset Management LLC | 8,643 | $96.0K |
| Tower Research Capital LLC (TRC) | 583 | $6.00K |
| Cutler Group LP | 333 | $3.00K |
| JPMorgan Chase & Co | 10 | $0 |